Aprogen Biologics Inc.

KOSE:A003060 Stock Report

Market Cap: ₩127.2b

Aprogen Biologics Past Earnings Performance

Past criteria checks 0/6

Aprogen Biologics's earnings have been declining at an average annual rate of -73.2%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been growing at an average rate of 10.5% per year.

Key information

-73.2%

Earnings growth rate

-50.7%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate10.5%
Return on equity-34.0%
Net Margin-208.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Risks Still Elevated At These Prices As Aprogen Biologics Inc. (KRX:003060) Shares Dive 26%

Jun 20
Risks Still Elevated At These Prices As Aprogen Biologics Inc. (KRX:003060) Shares Dive 26%

More Unpleasant Surprises Could Be In Store For Aprogen Biologics Inc.'s (KRX:003060) Shares After Tumbling 28%

Apr 18
More Unpleasant Surprises Could Be In Store For Aprogen Biologics Inc.'s (KRX:003060) Shares After Tumbling 28%

We Wouldn't Rely On Aprogen pharmaceuticalsInc's (KRX:003060) Statutory Earnings As A Guide

Jan 16
We Wouldn't Rely On Aprogen pharmaceuticalsInc's (KRX:003060) Statutory Earnings As A Guide

Aprogen pharmaceuticals,Inc.'s (KRX:003060) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Dec 20
Aprogen pharmaceuticals,Inc.'s (KRX:003060) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Is Aprogen pharmaceuticalsInc (KRX:003060) A Risky Investment?

Nov 24
Is Aprogen pharmaceuticalsInc (KRX:003060) A Risky Investment?

Revenue & Expenses Breakdown

How Aprogen Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A003060 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2468,033-141,77449,44323,235
30 Jun 2473,635-131,14450,60920,437
31 Mar 2485,518-125,38352,44419,396
31 Dec 2387,364-118,27042,97715,000
30 Sep 2381,744-19,22218,9629,563
30 Jun 2377,627-9,88919,3055,962
31 Mar 2365,77910,91618,5541,654
31 Dec 2265,19012,63926,6892,187
30 Sep 2262,48112,17227,6612,130
30 Jun 2261,13010,38427,3452,130
31 Mar 2261,0638,98427,2742,356
31 Dec 2156,4828,10326,0961,735
30 Sep 2154,6825,47225,2701,384
30 Jun 2153,4287,32524,4051,384
31 Mar 2151,7629,40621,5481,282
31 Dec 2053,32011,25322,047698
30 Sep 2055,4889,17921,760499
30 Jun 2054,2082,73220,730499
31 Mar 2053,45151221,640235
31 Dec 1950,904-8,31520,675336
30 Sep 1949,155-10,21219,383299
30 Jun 1947,488-4,35718,951299
31 Mar 1945,681-4,33618,508201
31 Dec 1845,395-1,21517,918192
30 Sep 1844,5622,03317,725179
30 Jun 1845,382-11,47617,419179
31 Mar 1845,555-16,23218,244289
31 Dec 1746,101-16,36523,368180
30 Sep 1745,925-17,83823,441203
30 Jun 1745,058-8,98723,572203
31 Mar 1745,066-5,95322,632122
31 Dec 1644,122-3,91817,55185
30 Sep 1644,322-2216,80597
30 Jun 1642,78394215,95297
31 Mar 1641,3842,84815,276105
31 Dec 1540,3242,76114,399135
30 Sep 1536,0261,17515,624112
30 Jun 1536,098-41015,873112
31 Mar 1534,713-2,70815,63686
31 Dec 1433,092-3,88715,38645
30 Sep 1429,623-10,48117,87144
30 Jun 1429,415-10,77217,47944
31 Mar 1429,543-16,46119,42243
31 Dec 1329,543-20,85222,871105

Quality Earnings: A003060 is currently unprofitable.

Growing Profit Margin: A003060 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A003060 is unprofitable, and losses have increased over the past 5 years at a rate of 73.2% per year.

Accelerating Growth: Unable to compare A003060's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A003060 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22.3%).

Return on Equity

High ROE: A003060 has a negative Return on Equity (-33.99%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 08:20
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aprogen Biologics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution